Modulation of pancreatic somatostatin by adrenergic and cholinergic agonism and by hyper- and hypoglycemic sulfonamides.
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D003981:Diazoxide / Q000494:pharmacology; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology*; D005934:Glucagon / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013004:Somatostatin / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology*; D014044:Tolbutamide / Q000494:pharmacology
D007328:Insulin; D013449:Sulfonamides; D013004:Somatostatin; D005934:Glucagon; D014044:Tolbutamide; D011433:Propranolol; D007545:Isoproterenol; D000109:Acetylcholine; D003981:Diazoxide; D004837:Epinephrine; D010646:Phentolamine